Comparison of Pharmacy Claims and Electronic Pill Bottles for Measurement of Medication Adherence Among Myocardial Infarction Patients.


Journal

Medical care
ISSN: 1537-1948
Titre abrégé: Med Care
Pays: United States
ID NLM: 0230027

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 26 7 2018
medline: 14 6 2019
entrez: 26 7 2018
Statut: ppublish

Résumé

Medication adherence after myocardial infarction remains low. Pharmacy claims have typically been used to measure medication adherence, but electronic pill bottles may offer additional information. The main objectives of this study were to compare the association of adherence measured by prescription claims and remote monitoring technologies with cardiovascular events. This study was a secondary analysis of a remote monitoring intervention to increase medication adherence in myocardial infarction patients. In total, 682 myocardial infarction patients were randomized to the intervention group with both medical and pharmacy benefits. Pharmacy claims adherence was measured using proportion of days covered (PDC) and GlowCap adherence (GC) was measured as the proportion of days the pill bottle was opened. We compared the association of PDC and GC adherence for statins with time to first vascular readmission or death and assessed model fit using Akaike information criterion and Bayesian information criterion and the likelihood ratio test. Higher PDC was significantly associated with a lower hazard rate for vascular readmissions or death (hazard ratio=0.435; P=0.009). There was also an association between GC adherence and vascular readmissions or death (hazard ratio=0.313; P≤0.001). Adding the GC adherence variable to the model using only PDC improved the model fit (likelihood ratio test, P=0.001), as well as vice versa (P=0.050). Pharmacy claims data provide useful but not complete data for medication adherence monitoring. New wireless technologies have the potential to provide additional data about clinical outcomes.

Sections du résumé

BACKGROUND
Medication adherence after myocardial infarction remains low. Pharmacy claims have typically been used to measure medication adherence, but electronic pill bottles may offer additional information.
OBJECTIVE
The main objectives of this study were to compare the association of adherence measured by prescription claims and remote monitoring technologies with cardiovascular events.
RESEARCH DESIGN
This study was a secondary analysis of a remote monitoring intervention to increase medication adherence in myocardial infarction patients.
SUBJECTS
In total, 682 myocardial infarction patients were randomized to the intervention group with both medical and pharmacy benefits.
MEASURES
Pharmacy claims adherence was measured using proportion of days covered (PDC) and GlowCap adherence (GC) was measured as the proportion of days the pill bottle was opened. We compared the association of PDC and GC adherence for statins with time to first vascular readmission or death and assessed model fit using Akaike information criterion and Bayesian information criterion and the likelihood ratio test.
RESULTS
Higher PDC was significantly associated with a lower hazard rate for vascular readmissions or death (hazard ratio=0.435; P=0.009). There was also an association between GC adherence and vascular readmissions or death (hazard ratio=0.313; P≤0.001). Adding the GC adherence variable to the model using only PDC improved the model fit (likelihood ratio test, P=0.001), as well as vice versa (P=0.050).
CONCLUSIONS
Pharmacy claims data provide useful but not complete data for medication adherence monitoring. New wireless technologies have the potential to provide additional data about clinical outcomes.

Identifiants

pubmed: 30045159
doi: 10.1097/MLR.0000000000000950
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Comparative Study Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e9-e14

Auteurs

Shivan J Mehta (SJ)

Department of Medicine, Perelman School of Medicine.
Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.
Penn Medicine Center for Health Care Innovation.

David A Asch (DA)

Department of Medicine, Perelman School of Medicine.
Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.
Penn Medicine Center for Health Care Innovation.
Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, PA.

Andrea B Troxel (AB)

Department of Population Health, Division of Biostatistics, NYU School of Medicine, New York, NY.

Raymond Lim (R)

Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.
Penn Medicine Center for Health Care Innovation.

Jennifer Lewey (J)

Department of Medicine, Perelman School of Medicine.

Wenli Wang (W)

Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.

Jingsan Zhu (J)

Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.

Laurie Norton (L)

Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.

Noora Marcus (N)

Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.

Kevin G Volpp (KG)

Department of Medicine, Perelman School of Medicine.
Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania.
Penn Medicine Center for Health Care Innovation.
Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH